ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > CD20 > CD0-H52H1

Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc)

  • Synonym
    MS4A1,CD20,MS4A-1
  • Source
    Human CD20 Full Length, His Tag(CD0-H52H1) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
    Predicted N-terminus: Met 1
  • Molecular Characterization
    CD20 Structure

    The CD20 carries a polyhistidine tag at the C-terminus with calculated MW of 35.2 kDa and migrates as 40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. The membrane scaffold protein (MSP1D1) has calculated MW of 24.7 kDa, and it migrates as 25 kDa under reducing (R) condition (SDS-PAGE).

    Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by a membrane scaffold protein (MSP1D1) coat that confers enhanced stability and a narrow particle size distribution.

    The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein(MSP1D1) upon removal of the detergent.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >85% as determined by SDS-PAGE.

  • Formulation

    Supplied as 0.2 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 6 months under sterile conditions.
*The isotype control of empty/mock nanodisc (Cat. No. APO-H51H3) is sold separately and not included in protein, you can follow this link for product information.
SDS-PAGE
CD20 SDS-PAGE

Human CD20 Full Length, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85%.

Bioactivity-ELISA
 CD20 ELISA

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) with a linear range of 1-63 ng/mL (QC tested).

 CD20 ELISA

Immobilized Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) at 5 μg/mL (100 μL/well) can bind Biosimilar of Obinutuzumab with a linear range of 0.3-5 ng/mL (Routinely tested).

Bioactivity-BLI
 CD20 BLI

Loaded Rituximab on Protein A Biosensor, can bind with Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) an affinity constant of 12.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Bioactivity-FACS
 CD20 FACS

2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (HEK293)(Cat. No. CD0-H52H1) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (QC tested).

  • Background
    B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 392,000

価格(JPY) : 1,456,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:31 Details
  • Number of Drugs in Clinical Trials:103 Details
  • Latest Research Phase:Approved

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone